Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication

Vaccine

Volumn 28, Issue 32, 2010, Pages 5315-5322

  Marconescu, Praveena S ^a   Smallshaw, Joan E ^a,b   Pop, Laurentiu M ^a   Ruback, Stephen L ^a   Vitetta, Ellen S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Intradermal; Ricin; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTITOXIN; RICIN; RIVAX; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOLOGICAL ADJUVANT; SUBUNIT VACCINE; VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; DRUG FORMULATION; DRUG SAFETY; FEMALE; IMMUNOGENICITY; LD 50; LUNG FUNCTION; LUNG INJURY; MOUSE; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SURVIVAL; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG; MUCOSA; PATHOPHYSIOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; FEMALE; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; LUNG; MICE; MUCOUS MEMBRANE; RICIN; VACCINATION; VACCINES; VACCINES, SUBUNIT;

EID: 77954958642     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.045     Document Type: Article

References (35)

1. Lord J.M., Roberts L.M., Robertus J.D. Ricin: structure, mode of action, and some current applications. FASEB J 1994, 8(2):201-208.
2. Audi J., Belson M., Patel M., Schier J., Osterloh J. Ricin poisoning: a comprehensive review. JAMA 2005, 294(18):2342-2351.
3. Foxwell B.M., Detre S.I., Donovan T.A., Thorpe P.E. The use of anti-ricin antibodies to protect mice intoxicated with ricin. Toxicology 1985, 34(1):79-88.
4. Lemley P.V., Wright D.C. Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge. Immunology 1992, 76(3):511-513.
5. Roche J.K., Stone M.K., Gross L.K., Lindner M., Seaner R., Pincus S.H., et al. Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 2008, 88(11):1178-1191.
6. Miller D.J., Ravikumar K., Shen H., Suh J.K., Kerwin S.M., Robertus J.D. Structure-based design and characterization of novel platforms for ricin and shiga toxin inhibition. J Med Chem 2002, 45(1):90-98.
7. Mabley J.G., Pacher P., Szabo C. Activation of the cholinergic antiinflammatory pathway reduces ricin-induced mortality and organ failure in mice. Mol Med 2009, 15(5-6):166-172.
8. Griffiths G.D., Phillips G.J., Holley J. Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal Toxicol 2007, 19(10):873-887.
9. Kende M., Del Giudice G., Rivera N., Hewetson J. Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant. Vaccine 2006, 24(12):2213-2221.
10. Marsden C.J., Knight S., Smith D.C., Day P.J., Roberts L.M., Phillips G.J., et al. Insertional mutagenesis of ricin A chain: a novel route to an anti-ricin vaccine. Vaccine 2004, 22(21-22):2800-2805.
11. Olson M.A., Carra J.H., Roxas-Duncan V., Wannemacher R.W., Smith L.A., Millard C.B. Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 2004, 17(4):391-397.
12. Baluna R., Rizo J., Gordon B.E., Ghetie V., Vitetta E.S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999, 96(7):3957-3962.
13. Smallshaw J.E., Firan A., Fulmer J.R., Ruback S.L., Ghetie V., Vitetta E.S. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 2002, 20(27-28):3422-3427.
14. Smallshaw J.E., Richardson J.A., Pincus S., Schindler J., Vitetta E.S. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 2005, 23(39):4775-4784.
15. Legler PM, Brey RN, Vitteta ES, Millard CB, Chain A, Structure of Rivax: a human ricin vaccine, in Protein Database: Molecule 3BJG_A; 2007.
16. Smallshaw J.E., Richardson J.A., Vitetta E.S. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 2007, 25(42):7459-7469.
17. Vitetta E.S., Smallshaw J.E., Coleman E., Jafri H., Foster C., Munford R., et al. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci USA 2006, 103(7):2268-2273.
18. Smallshaw J.E., Vitetta E.S. A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity. Vaccine 2010, 28:2428-2435.
19. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12(5):387-400.
20. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(1):68-89.
21. Patel S.M., Atmar R.L., Sahly H.E., Cate T.R., Keitel W.A. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 2009.
22. Frosner G., Steffen R., Herzog C. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. J Travel Med 2009, 16(6):413-419.
23. Wahl M., Hermodsson S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response. Scand J Infect Dis 1987, 19(6):617-621.
24. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M.P., Weber F., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27(52):7304-7312.
25. Propst T., Propst A., Lhotta K., Vogel W., Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998, 32(6):1041-1045.
26. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(1):23-29.
27. Chiu S.S., Peiris J.S., Chan K.H., Wong W.H., Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007, 119(6):1076-1082.
28. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351(22):2286-2294.
29. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(22):2295-2301.
30. Hauge S., Madhun A., Cox R.J., Haaheim L.R. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol 2007, 14(8):978-983.
31. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines-US perspective. Vaccine 2002, 20(Suppl. 3):S18-S23.
32. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25(30):5467-5484.
33. Janeway Immunobiology: the immune system in health and disease 2005, Garland Science. 6th ed.
34. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29(3):497-510.
35. Chang S.Y., Cha H.R., Igarashi O., Rennert P.D., Kissenpfennig A., Malissen B., et al. Cutting edge: Langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J Immunol 2008, 180(7):4361-4365.